Delivery Order SPE2DB20D1109-SPE2DB25FP60N
- Not listed
- The Defense Logistics Agency awarded a $32,614.21 delivery order to AmerisourceBergen Drug Corp for Skyrizi 150 mg/ml pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The pharmaceutical product will...
- The Defense Logistics Agency awarded a $12,962.95 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of SKYRIZI 150 mg/ml pen injections. This is a firm fixed-price contract with an ultimate completion date of July 28, 2025, and was competitively awarded with no set-aside designation. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order valued at $24,512.38 to AmerisourceBergen Drug Corp for the supply of Skyrizi 150 mg/mL pen injections. This competitively awarded, firm fixed-price contract was issued on August 13, 2025, with an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order with no set-aside designation, reflecting open...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $25,142.34 for SKYRIZI 150 mg/mL pen injectors on August 4, 2025, with completion scheduled for August 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- AmerisourceBergen Drug Corp was awarded a $19,250.64 firm fixed price delivery order by the Defense Logistics Agency's Medical Supply Chain on July 28, 2025, for the supply of Skyrizi 150 mg/ml pen injectors. This non-set-aside, competitively awarded contract is classified as a child award under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product is scheduled for delivery to...
- The Defense Logistics Agency awarded a delivery order valued at $113,263.44 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of SKYRIZI 150 mg/mL pen injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation, with performance to be completed by August 8, 2025, at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop...
- The Defense Logistics Agency awarded a $17,574.35 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen vials under a firm fixed price contract type. This competitive award, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The delivery location is specified as Conshohocken, Pennsylvania, the company's corporate...
- The Defense Logistics Agency awarded a $11,830.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 MG/2.4 ML on-body injectors, with an ultimate completion date of September 9, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,797.51 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen injectors. This competitive award, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed-price delivery order with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $50,801.12 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of SKYRIZI 150 mg/mL pen/mL, a pharmaceutical product used to treat inflammatory conditions. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the prime contractor. The order is scheduled for completion by July 24, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP60NDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $23,364.42 to supply Skyrizi 150 mg/ml pen injections, with an ultimate completion date of August 20, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively to the pharmaceutical distributor's Conshohocken, Pennsylvania location. The contract represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, serves military and veteran healthcare systems through its extensive portfolio of medical product deliveries with the Defense Logistics Agency and its Medical Supply Chain. The company's federal contract awards demonstrate versatility in fulfilling federal medical supply needs across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, vaccines, and medical devices. This delivery order for Skyrizi, a prescription biologic used in dermatological treatment, reflects the company's continued role as a primary pharmaceutical supplier supporting Department of Defense healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.4k | 8/19/25 |